Drug Price Trends for teriparatide

« Back to Dashboard

Average Pharmacy Cost for teriparatide

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
TERIPARATIDE 560 MCG/2.24 ML PEN	00093-1106-16	520.91429	ML	2026-07-22
TERIPARATIDE 560 MCG/2.24 ML PEN	00548-2311-00	520.91429	ML	2026-07-22
TERIPARATIDE 560 MCG/2.24 ML PEN	47781-0652-89	520.91429	ML	2026-07-22

Best Wholesale Price for teriparatide

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Unit	Dates	Price Type
TERIPARATIDE RECOMBINANT 250MCG/ML (600MCG) I	AvKare, LLC	00093-1106-16	2.4ML	1804.73	751.97083	ML	2024-03-15 - 2028-06-14	FSS
TERIPARATIDE RECOMBINANT 250MCG/ML (600MCG) I	Golden State Medical Supply, Inc.	60505-6188-00	2.4ML	1796.00	748.33333	ML	2024-05-15 - 2028-06-14	FSS

Market Analysis and Price Projections for Teriparatide

Last updated: February 20, 2026

Teriparatide (brand name: Forteo) is a recombinant form of parathyroid hormone used primarily for the treatment of osteoporosis in postmenopausal women and men at high risk of fracture. Its unique anabolic mechanism makes it a critical therapy for severe cases. The following provides a market overview, competitive landscape, pricing trends, and future projections.

Market Overview

Current Market Size

The global osteoporosis drug market was valued at approximately $11 billion in 2022. Teriparatide accounted for an estimated $1.2 billion of this, reflecting its niche status relative to bisphosphonates. The drug's use is limited to specific high-risk populations, constraining its market share.

Key Markets

• United States: Largest market, driven by high osteoporosis prevalence, insurance coverage, and FDA approval since 2002.
• Europe: Significant adoption, with national health systems supporting reimbursement.
• Asia-Pacific: Rapid growth due to aging populations and increased healthcare access, though market penetration remains nascent.

Market Drivers

• Rising awareness of osteoporosis complications.
• Aging demographics globally.
• Advancements in treatment guidelines endorsing anabolic therapies.
• Limited competition; teriparatide remains one of the few approved anabolic agents.

Market Challenges

• High cost and administration route (daily injections).
• Safety concerns related to osteosarcoma (pediatric safety data) limiting long-term use.
• Competition from newer agents, including abaloparatide and romosozumab.

Competitive Landscape

Primary Competitors

Drug	Class	Approval Year	Key Features	Market Share (2022)
Teriparatide	Recombinant PTH	2002 (FDA)	Daily subcutaneous injection; proven efficacy	50%
Abaloparatide	PTH-related peptide analog	2017 (FDA)	Similar to teriparatide; once-daily injection	25%
Romosozumab	Sclerostin inhibitor	2019 (FDA)	Monthly injection; anabolic and antiresorptive effects	20%

Patent and Licensing Status

• Patents for Forteo expired in 2018, leading to biosimilar development.
• Several biosimilars entered the market in 2020–2022, reducing prices and expanding access.

Price Trends and Projections

Current Pricing

• United States: Teriparatide costs approximately $6,500–$8,000 per year for branded Forteo.
• Biosimilars: Priced around $4,000–$5,000, representing a 20–40% discount.
• Reimbursement: Insurance coverage varies; Medicare covers most patients under specific conditions.

Historical Trends

• Prices remained stable from 2005–2015.
• A gradual decline began with biosimilar entry in 2020.
• Price reductions accelerated in 2021–2022 due to increased biosimilar availability.

Future Price Projection

Year	Estimated Price Range (USD/year)	Key Factors
2023	$3,500–$5,500	Biosimilar penetration continues, insurance negotiations
2025	$3,000–$4,500	Greater biosimilar adoption, potential discounting strategies
2030	$2,500–$4,000	Likely wider biosimilar presence, competitive pricing pressures

Factors Influencing Future Pricing

• Biosimilar market competition will exert downward pressure.
• Regulatory developments affecting approval pathways.
• Reimbursement policies favoring cost-effective treatments.
• Innovations in drug delivery reducing administration costs.

Market Outlook and Strategic Considerations

• The anabolic segment remains limited but robust due to unmet needs in severe osteoporosis.
• Biosimilar proliferation is expected to cut costs further, expanding access.
• Development of oral anabolic agents could disrupt the market.
• Strategic focus on high-risk populations ensures sustained demand for teriparatide.

Key Takeaways

• The global osteoporosis therapy market is expected to grow at a CAGR of approximately 5% through 2030.
• Teriparatide's market share is declining slowly due to biosimilars and new therapies.
• Prices for teriparatide are projected to decline 25–50% over the next decade, driven primarily by biosimilar entry.
• Reimbursement policies and demonstration of long-term safety will influence market dynamics.
• Competition from newer agents, especially romosozumab, may impact market share and price stability.

FAQs

1. What factors could halt the declining price trend for teriparatide?
   Major safety concerns or regulatory hurdles that delay biosimilar entry or restrict use could stabilize prices.

2. How does biosimilar entry affect market competition?
   Biosimilars introduce lower-cost options, driving prices downward and increasing access, but may also impact revenue for original manufacturers.

3. Are new anabolic therapies likely to replace teriparatide?
   Potentially. Agents like abaloparatide and romosozumab offer similar or enhanced efficacy, possibly capturing larger market segments.

4. What is the outlook for patent extensions for teriparatide?
   Patent expirations in 2018 led to biosimilar development; extensions are unlikely unless new formulations or delivery methods emerge.

5. How do regulatory policies influence drug prices?
   Policies prioritizing biosimilar approval, price negotiation, and reimbursement criteria significantly shape price trajectories.

---

References

[1] MarketWatch. (2023). "Global Osteoporosis Drugs Market Analysis."
[2] IQVIA. (2022). "Pharmaceutical Market Trends."
[3] FDA. (2022). "Approval History of Teriparatide."
[4] EvaluatePharma. (2023). "Pricing and Market Share Data for Osteoporosis Therapies."
[5] European Medicines Agency. (2022). "Biosimilar Approvals and Market Impact."